STRONG-HF
2022
Safety, Tolerability and Efficacy of Rapid Optimization, helped by NT-proBNP testinG, of Heart Failure therapies
In 1,078 patients recently hospitalised for acute heart failure, rapid up-titration of guideline-directed therapy with close follow-up reduced 180-day death or heart-failure readmission compared with usual care.
Result
Efficacy: 180-day all-cause death or heart-failure readmissionadjusted RR 0.66 (95% CI 0.50-0.86) · P = 0.0021
Below 1 favours rapid up-titration of guideline-directed therapy with close follow-up, above 1 favours usual care.
- Absolute difference
- 8.1 points
- NNT
- 13
Absolute difference and NNT are derived from the event rates.
- Subtopic
- GDMT up-titration
- Design
- Multinational open-label RCT, stopped early for benefit
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2026 HFESC 2021 HF
- Source
- Mebazaa A, et al. Lancet. 2022;400(10367):1938-1952.doi 10.1016/S0140-6736(22)02076-1
Discussion & critique
Open-label design and intensive follow-up limit generalisability to routine care, and the primary endpoint was driven largely by HF readmission. Established rapid post-discharge up-titration of GDMT, reinforcing guideline emphasis on early optimisation.